Results 211 to 220 of about 548,791 (262)

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera   +24 more
wiley   +1 more source

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non‐Hodgkin Lymphoma on Reproduction Patterns

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Concerns about treatment‐related fertility impairment are common among young adult lymphoma survivors. Evidence on the impact of treatment for aggressive non‐Hodgkin lymphoma (NHL) on future childbearing is limited, although many individuals of reproductive age are affected.
Stefanie Antonilli   +10 more
wiley   +1 more source

Treatment Patterns, Outcomes and Survival Trends in T‐Cell Prolymphocytic Leukemia: A Nationwide Population‐Based Study in the Netherlands

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Background T‐cell prolymphocytic leukemia (T‐PLL) is a rare, aggressive mature T‐cell malignancy with limited therapeutic options. Alemtuzumab remains the backbone of therapy, and fit responders are consolidated with allogeneic stem cell transplantation (alloSCT). However, contemporary population‐level outcomes remain poorly defined.
Mirian Brink   +17 more
wiley   +1 more source

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Maria Dampmann   +16 more
wiley   +1 more source

Gene Editing for Haemophilia—The Next Frontier

open access: yesHaemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy